Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in thedb/dbmouse
- 15 September 2013
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 305 (6), F911-F918
- https://doi.org/10.1152/ajprenal.00643.2012
Abstract
Podocyte damage and accumulation of advanced glycation end products (AGEs) are characteristics of diabetic nephropathy (DN). The pathophysiology of AGE-challenged podocytes, such as hypertrophy, apoptosis, and reduced cell migration, is closely related to the induction of the cell cycle inhibitor p27Kip1and to the inhibition of neuropilin 1 (NRP1). We have previously demonstrated that treatment with erythropoietin is associated with protective effects for podocytes in vitro. db/ db mice with overt DN aged 15–16 wk were treated with either placebo, epoetin-β, or continuous erythropoietin receptor activator (CERA) for 2 wk. db/ db mice compared with nondiabetic db/ m control mice revealed the expected increases in body weight, blood glucose, albumin-to-creatinine ratio, and AGE accumulation. Whereas there were no differences in body weight, hyperglycemia and AGEs were observed among diabetic mice that received epoetin-β compared with CERA and placebo treatment, indicating that epoetin-β/CERA treatment does not interfere with the development of diabetes in this model. However, the albumin-to-creatinine ratio was significantly lower in db/ db mice treated with epoetin-β or CERA. Furthermore, kidney weights in db/ db mice were increased compared with db/ m control mice, indicating renal hypertrophy, whereas the increase in renal weight in epoetin-β- or CERA-treated db/ db mice was significantly lower than in placebo-treated control mice. Induction of p27Kip1and suppression of NRP1 were significantly reduced in the epoetin-β treatment group versus the CERA treatment group. Furthermore, erythropoietin treatment diminished the diabetes-induced podocyte loss. Together, independently from hematopoetic effects, epoetin-β or CERA treatment was associated with protective changes in DN, especially that NRP1 and p27Kip1expressions as well as numbers of podocytes returned to normal levels. Our data show, for the first time, that medication of overt DN with erythropoietin for a short time can ameliorate albuminuria and podocyte loss.Keywords
This publication has 41 references indexed in Scilit:
- Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injuryKidney International, 2012
- Human RAGE antibody protects against AGE-mediated podocyte dysfunctionNephrology Dialysis Transplantation, 2012
- Podocyte Biology for the BedsideAmerican Journal of Kidney Diseases, 2011
- Mouse models of diabetic nephropathyCurrent Opinion in Nephrology and Hypertension, 2011
- Deletion of the Receptor for Advanced Glycation End Products Reduces Glomerulosclerosis and Preserves Renal Function in the Diabetic OVE26 MouseDiabetes, 2010
- Diabetic nephropathyDiabetology & Metabolic Syndrome, 2009
- Advanced Glycation End Products Suppress Neuropilin-1 Expression in Podocytes by a Reduction in Sp1-Dependent Transcriptional ActivityAmerican Journal of Nephrology, 2009
- BMP Signaling and Podocyte Markers are Decreased in Human Diabetic Nephropathy in Association with CTGF OverexpressionJournal of Histochemistry & Cytochemistry, 2009
- p27Kip1 knockout mice are protected from diabetic nephropathy: Evidence for p27Kip1 haplotype insufficiencyKidney International, 2005
- Erythropoietin as an antiapoptotic, tissue-protective cytokineCell Death & Differentiation, 2004